

CrossRef DOI of original article:

PCO₂ gap -As an Endpoint of Resuscitation and Predictor of Mortality in Patients with Shock: A Prospective Observational Study

Dr. V. Viju Wilben

Received: 1 January 1970 Accepted: 1 January 1970 Published: 1 January 1970

Abstract

Introduction: Endpoint of resuscitation is essential to be determined objectively as we get more substantial evidence supporting the fact that both under resuscitation and over resuscitation is detrimental to overall outcomes. Since carbon dioxide is more diffusible than oxygen it readily gets in to the blood in low perfusion states whereas oxygen doesn't. Hence widening the PCO₂ gap. Since this PCO₂ gap can be determined easily in the ICU we propose that PCO₂ gap can be used as a reliable indicator of endpoint of resuscitation and predictor of mortality in patients with shock. Aim: To evaluate the association between PCO₂ gap and outcome of resuscitation in patients with shock. The Objectives of the project are to study the association between PCO₂ difference and in-hospital mortality in patients admitted with shock and to study the correlation between PCO₂ difference and lactate clearance.

Index terms—

1 Introduction

Shock is the clinical expression of circulatory failure that results in inadequate cellular oxygen utilization. Shock is a common condition in critical care, affecting about one third of patients in the intensive care unit (ICU), both over resuscitation and under resuscitation can adversely impact the outcomes. End point of resuscitation has always been a matter of debate, initially continuous ScvO₂ monitoring as introduced by Rivers et al had the obvious limitation that normal/high values cannot discriminate whether delivery is adequate or in excess to demand. High ScvO₂ profiles have even been shown to be related to elevated blood lactate concentration and poor survival rates. Lactate cannot differentiate between different etiologies of shock and it can get elevated in various other conditions. Carbon dioxide (CO₂) is highly diffusible and can be a marker of adequacy of venous return, the central venous and arterial CO₂ gap, as an easily available clinical monitoring tool. Observational study has shown that Persistence of such a large pCO₂ gap after 24 hours of treatment was predictive of higher mortality. In conclusion, determining the PCO₂ gap during resuscitation of critically ill patients is useful in deciding when to stop resuscitation. Central venous-arterial carbon dioxide difference (PCO₂ gap) can be a marker of cardiac output adequacy in global metabolic conditions that are less affected by the impairment of oxygen extraction capacity. Assessing the adequacy of oxygen delivery with oxygen requirements is one of the key-goal of hemodynamic resuscitation. Clinical examination, lactate and central or mixed venous oxygen saturation (SvO₂ and ScvO₂, respectively) all have their limitations. Many of them may be overcome by the use of the carbon dioxide (CO₂)-derived variables. The venoarterial difference in CO₂ tension ("∆PCO₂" or "PCO₂ gap") is not an indicator of anaerobic metabolism since it is influenced by the oxygen consumption. By contrast, it reliably indicates whether blood flow is sufficient to carry CO₂ from the peripheral tissue to the lungs in view of its clearance: it, thus, reflects the adequacy of cardiac output with the metabolic condition. We investigate the relation between be determined objectively as we get more substantial evidence supporting the fact that both under resuscitation and over resuscitation is detrimental to overall outcomes. Since carbon dioxide is more diffusible than oxygen it readily gets in to the blood in low perfusion states whereas oxygen doesn't. Hence widening the PCO₂ gap. Since this PCO₂ gap can be determined easily in the ICU we propose that PCO₂

gap can be used as a reliable indicator of endpoint of resuscitation and predictor of mortality in patients with shock.

Aim: To evaluate the association between PCO₂ gap and outcome of resuscitation in patients with shock. The Objectives of the project are to study the association between PCO₂ difference and in-hospital mortality in patients admitted with shock and to study the correlation between PCO₂ difference and lactate clearance.

Materials and methods: 71 adult patients presenting with shock to our ER were enrolled in the study. They were resuscitated according to standard protocols. PCO₂ gap was measured at presentation, then every 2 hours until the resolution of shock which were correlated to the lactate clearance, hemodynamics and the IVC index of the patient. The data was then analyzed using the R software and logistic regression was done to analyze various factors associated with mortality. P value less than 0.05 was considered statistically significant.

Results: The correlation between pCO₂ gap and the in hospital mortality was statistically significant at 0,2,4,6 and 24 hours. The correlation between pCO₂ gap and the end point of resuscitation was statistically significant at 2,4,6 and 24 hours implied by the pearson's correlation. We also found a positive correlation between PCO₂ gap and lactate clearance which was statistically significant.

2 Conclusion:

The PCO₂ gap can be used a marker of the adequacy of the cardiac output in patients with shock. Using pCO₂ gap has potential to avoid administration of unnecessary fluids and inotropes in patients, who have lactate elevated in the absence of tissue hypo perfusion. We suggest using pCO₂ gap as a complementary tool to evaluate the adequacy of blood flow to global metabolic demand. A high pCO₂ gap on initial presentation was associated with high mortality rates. So it can be used as a predictor of outcomes in patients with shock.

3 PCO₂ gap -

4 Review of Literature

Shock is defined as inability to maintain MAP which is refractory to fluid resuscitation. It has a guarded prognosis, there are many upstream and downstream markers for resuscitation, septic shock guidelines endorses Lactate as a prognostic marker; has got its own limitations as it can be elevated in other clinical conditions and it cannot differentiate the cause of shock. With enough evidence coming up about over resuscitation and positive balance being one of the predictor of mortality there is a need for ideal resuscitation marker which can be easily employed bedside with present day equipment used on day to day basis.

CO₂ is the end product of aerobic metabolism, PCO₂ in the venous blood reflects the global tissue blood flow relative to metabolic demand. CO₂ is about 20 times more soluble than O₂ so it more reliably diffuses out of ischemic tissues into the venous effluent making it a sensitive marker of hypoperfusion in situations where an O₂ diffusion barrier exists (e.g. nonfunctional and obliterated capillaries), "masking" poor O₂ extraction (O₂ER) and increased tissue O₂ debt, CO₂ still diffuses to the venous effluent, "unmasking" the low perfusion state for the clinician when venous-to-arterial CO₂ difference is evaluated the gap is a marker of adequacy of venous blood flow to remove CO₂ produced rather than a marker of tissue hypoxia or dysoxia.

5 Table 1: PCO₂ Gap in Different Shock States

Conversely, in HH, pCO₂ gap did not increase in spite of a marked VO₂ and VCO₂ reduction. There is a good correlation between Mixed CO₂ and Central CO₂ difference with Arterial CO₂ as demonstrated by Van Beest et al in severe sepsis and septic shock patients, hence Central CO₂ can be substituted for mixed CO₂ for determining the CO₂ gap which acts as surrogate marker for Cardiac Index. Cushieri J et al conducted study in ICU patients to see the correlation between Central Venous and Arterial CO₂ gap and Cardiac index determined by thermodilution technique and showed statistically significant correlation. Hence CO₂ gap can be used as a marker of Cardiac output.

6 a) Role in Sepsis

In sepsis although Cardiac output may be normal but regional compromise of circulation is well documented phenomenon which may lead to increase in CO₂ secondary to micro-circulation compromise. P(cv-a)CO₂ could be considered as a better indirect assessment of systemic blood flow than ScvO₂ in resuscitated-septic shock patients. A cutoff value for pCO₂ gap of 0.8 kPa (6mmHg) discriminated between high and low lactate clearance and CI. In study done by Vallee et al done in septic shock patients compared When the 70% ScvO₂ goal value is reached, the presence of a P(cva)CO₂ larger than 6 mmHg shown to be an useful tool to identify patients who still remain inadequately resuscitated. We hypothesize that CO₂ gap is non inferior to lactate clearance in resuscitation of critically ill patients.

As illustrated in table 1, Lactate is high in all types of shock, PCO₂ Gap is high in cardiogenic and distributive shock which is amenable to fluid resuscitation and inotropic support and low in hypoxemic and cytopathic shock where fluid resuscitation has no role thus it can be concluded that PCO₂ gap is useful in determining when to start and stop fluid resuscitation. CO₂ gap is a marker of adequacy of venous blood rather than marker of tissue hypoxia or dysoxia as shown by Vallet et al in an experimental model of isolated limb in which ischemic

hypoxia (IH) and hypoxic hypoxia (HH). The authors demonstrated that when DO₂ was reduced beyond its critical threshold in IH (dysoxia), this was associated with an increased limb venous-to-arterial PCO₂gap. 12 III.

7 Research Question

Would pCO₂ gap serve as an ideal bedside marker to predict the outcome of resuscitation in a patient with shock?

V.

8 Methods and Methodology

9 Statistical Methods

10 a) Sample Size Calculation

Sample size was calculated using nMaster software v2.0

In a study done by Beest PV et al, the mortality of patients with sepsis was 24.5% (13 out of 53) and risk of mortality for those with high PCO₂ gap ranged from 1.6 to 5. 3 Keeping a conservative value in odds ratio as 2.5, with power of 80% and 5% alpha error the minimum required sample size is 71.

11 b) Statistical Analysis Plan

Data was analyzed using R software. Continuous variable were described using mean and standard deviation. Categorical variables were described using frequency and percentage. Patients were categorized based on PCO₂ difference and logistic regression was done to analyze various factors associated with mortality. Correlation between PCO₂ difference and lactate was done using appropriate statistical methods. P value less than 0.05 was considered statistically significant.

12 c) Ethical consideration

Ethical clearance was obtained prior to the study from the ethics committee of the institution. Informed consent was obtained from the patient or guardian before the onset of study. Confidentiality of

13 Aims and Objectives

Aim of the Project: To study the association between PCO₂ gap and outcome of resuscitation in patients with shock.

Objectives of the Project: The Objectives of the project are as follows:

? Primary objectives-To study the association between PCO₂ gap and in-hospital mortality in patients admitted with shock.

? Secondary objectives ? To study the correlation between PCO₂ gap and lactate clearance. ? To study the role of PCO₂ gap as a marker for endpoint of resuscitation in patients with shock.

patient details are and will be maintained. It was explained to the patient that the study is purely descriptive and merely for data collection. There is no intervention required specifically for the study. Management of these patients were along the standard international guidelines. As the study did not involve any extra procedure, no compensation was offered during and after the study.

VIII.

14 Results

A total of 71 patients were enrolled in the study. 7 patients died from the 48 to 72 hours time period. Their samples were collected and analyzed till the 24th hour of admission. The mean age of the patients was 54 years (SD 16.2; range 18-81 years). The primary outcome of the study was the correlation between the PCO₂ gap and the in hospital mortality at each of the sampling time points. The correlation between the PCO₂ gap and the in hospital mortality was positive at 0, 2, 4, 6 and 24hours. The correlation was statistically significant at 0 and 2 hours. (Table 2) There was a statistically significant negative correlation between end point of resuscitation and pCO₂ gap at 2h,4h, 6h and 24 hours as implied by the Pearson's correlation in Table 3.

15 Discussion

The association of lactate accumulation and oxygen debt during shock states has been described for decades¹⁵. Throughout the years, there has been continued interest in refining resuscitation triggers, and response to therapy. Lactate clearance as an endpoint of resuscitation is supported by at least two multi-center studie^{16,17}.

However, lactate clearance has disadvantages as lactates can sometimes be normal in septic shock¹⁸, lactate elevation not solely due to oxygen delivery-consumption mismatch and it has different prognostic implications based on the initial value.

It was recognized in sepsis that pCO₂ gap (or its mathematical derivatives) outperformed other markers in detecting tissue hypoperfusion^{13,[19][20][21]}. The arterial carbon dioxide is dependent on the pulmonary gas

exchange and the venous carbon dioxide is dependent on the blood flow to the tissue 22 . So, when the flow reduces in low cardiac output states like shock, the difference between the venous and arterial carbon dioxide increases. It has been demonstrated that the pCO₂ gap increases in various types of shock. 2 In our study we found a statistically significant correlation of pCO₂ gap at 0 hour and and 2nd hour of resuscitation and mortality in patients. It shows that high pCO₂ gap on initial presentation can be used as a predictor of outcomes in patients with shock. Ospina-Tascón, G.A. et al., 24 found that the persistence of high PCO₂gap during the early resuscitation of septic shock was associated with higher 28 day mortality.

We also found that there was a statistically significant correlation between end point of resuscitation and pCO₂ gap at 2h,4h, 6h and 24 hours. Hence, pco₂ gap can be used as an endpoint of resuscitation in patients with shock. This was similar to the findings of Vallet B et al., 11 who found that determining the gap during resuscitation of critically ill patients is useful when deciding when to stop resuscitation.

Our analysis also showed that PCO₂ gap at various time points had positive correlation with lactate clearance. This was similar to a study done by Shyam M et al., 25 who showed that the PcvCO₂-PaCO₂/CaO₂-CcvO₂ ratio and lactate are positively correlated during the first 24 hours of active resuscitation from sepsisinduced hypotension, Pco₂ gap is not inferior to lactate levels as a hemodynamic marker. It can be substituted in place of lactate levels to predict outcomes in patients presenting with shock. It can also be used as a guide for therapy to achieve endpoint of resuscitation.

X.

16 Limitations

Our study has its limitations. It is a descriptive study without randomization of the patients. Also some technical aspects should be kept in mind when these indices are used in clinical practice. First, some errors in the PCO₂ gap measurements may occur when sampling the venous blood: incorrect sample container, contaminated sample by air or venous blood or catheter fluid. Second, a too long delay of transport of blood sampling may significantly change the blood gas content at the venous and the arterial site.

17 Summary and Conclusion

The PCO₂ gap can be used a marker of the adequacy of the cardiac output in patients with shock. Using pCO₂ gap has potential to avoid administration of unnecessary fluids and inotropes in patients, who have lactate elevated in the absence of tissue hypo perfusion. We suggest using pCO₂ gap as a complementary tool to evaluate the adequacy of blood flow to global metabolic demand. A high pCO₂ gap on initial presentation was associated with high mortality rates. So it can be used as a predictor of outcomes in patients with shock. There may be some words that you do not understand. Please ask me to stop as we go through the information and I will take time to explain. If you have questions later, you can ask them of me, or the staff.

18 List of abbreviations

19 ICU

pCO₂ gap is the difference between the venous and arterial carbon dioxide. When a patient presents with shock, they will be treated with IV fluids or medication to increase blood pressure (inotropes) by constriction of blood vessels depending upon the cause of the shock. To know when the shock has resolved, we are going to compare pCO₂ gap to other parameters which have been previously established.

20 Purpose of the research

To evaluate if pCO₂ gap can be used to predict mortality and marker for end point of resuscitation

21 Participant selection

We are inviting all adults with shock to participate in the research on pCO₂ gap.

22 Voluntary Participation

Your participation in this research is entirely voluntary. It is your choice whether to participate or not. Whether you choose to participate or not, all the services you receive at the hospital will continue and nothing will change. You may change your mind later and stop participating even if you agreed earlier.

23 Procedures and Protocol

Once you understand the study and give consent, your pCO₂ gap will be measured on presentation, 2nd hour, 4th hour, 6th hour and at 24th hour. Patients presenting with shock will have an arterial line for invasive blood pressure measurement and a central line for administration of inotropes to treat the shock. Blood samples from these lines will help us to measure pCO₂ gap. Treatment will be given for the shock as per standard guidelines and hospital protocol according to the patient's condition. Other parameters such as mean arterial pressure,

206 IVC collapsibility, lactates will be compared to find out if pCO₂ gap has a good correlation for endpoint of
207 resuscitation (resolution of shock)

208 **24 Duration**

209 The research takes place over the course of 1 year. You will be followed up for 12 to 24 hours depending upon
210 your clinical condition.

211 **25 Side Effects**

212 No new intervention or procedure is done for the study. You will already have lines from which blood samples
213 will be taken. Hence there are no side effects for the study.

214 **26 Risks**

215 No additional risks and discomfort will be caused during this study.

216 **27 Benefits**

217 The findings of this study can change the views of using pCO₂ gap as an endpoint of resuscitation. I confirm
218 that the participant was given an opportunity to ask questions about the study, and all the questions asked by
219 the participant have been answered correctly and to the best of my ability. I confirm that the individual has not
220 been coerced into giving consent, and the consent has been given freely and voluntarily.

A copy of this ICF has been provided to the participant. ^{1 2}

| Shock type | Lactate | O ₂ ER | ScvO ₂ | cvaCO ₂ gap |
|----------------------------|---------|-------------------|-------------------|------------------------|
| Cardiogenic or hypovolemic | HIGH | HIGH | LOW | HIGH |
| Anemic or hypoxemic | HIGH | HIGH | LOW | LOW |
| Distributive | HIGH | LOW | HIGH | HIGH |
| Cytopathic | HIGH | LOW | HIGH | LOW |

Figure 1:

221

¹PCO₂ gap -As an Endpoint of Resuscitation and Predictor of Mortality in Patients with Shock: A Prospective Observational Study

²B © 2022 Global Journals PCO₂ gap -As an Endpoint of Resuscitation and Predictor of Mortality in Patients with Shock: A Prospective Observational Study

Date: 2nd Feb 2021

NHH/AEC-CL-2020-506

Dr. Prabhu S
Department of Emergency Medicine
Narayana Hrudayalaya Hospitals, Bommasandra
Bangalore-560099

Study Title: PCO2 Gap – As An Endpoint Of Resuscitation And Predictor Of Mortality In Patients With Shock: A Prospective Observational Study

Subject: Approval letter for above mentioned study

Dear Dr. Prabhu S


We have received soft copy of the study documents vide your letter dated 9th April 2020. The study protocol was reviewed by Scientific Research Committee (SRC) in its meeting on 15th April 2020 and approved for Scientific content. The following Scientific Research Committee members were present during the meeting held on 15th April 2020 at 2.00 pm

| # | Name of the Member | Designation | Present/ Not Present |
|----|---|------------------------|----------------------|
| 1 | Dr. Muralidhar Kanchi | Chairperson | Present |
| 2 | Dr. Alben Sigamani | Vice – Chairperson | Present |
| 3 | Dr. Arun Kumar/ Ms. Sherin Manichen/ Ms. Delitia Manuel | Biostatistician | Present |
| 4 | Dr. Arkasubhra Ghosh | Local Teaching Faculty | Absent |
| 5 | Dr. Vikneswaran | Basic Science Faculty | Present |
| 6 | Dr. Sanjay Rao | Clinician | Absent |
| 7 | Dr. Viju Wilben | | Present |
| 8 | Dr. Radhika Manohar | | Absent |
| 9 | Dr. Murali Mohan | | Absent |
| 10 | Dr. Gayathri Gopalakrishnan | | Absent |
| 11 | Dr. Rohit Raghunath Randae | | Absent |

The study was further reviewed in NHAEC meeting held on 24th April 2020 and approved, pending some clarification from principal investigator. The clarification provided were reviewed by Ethics Committee and the NHAEC has decided to approve this study for scientific and ethical content. You are hereby permitted to conduct this study at Mazumdar Shaw Medical Centre, a unit of Narayana Hrudayalaya Ltd.

Documents Reviewed:

- Protocol, Version 1.2, Dated 5th June 2020
- Informed consent form & Patient information sheet, Version 1.0 Dated 14th Sept 2020
- Informed consent form & Patient information sheet for relative/representative Version 2.0 Dated 14th Sept 2020
- Deferred consent for research participation version 2.0 dated 14th Sept 2020


Narayana Hrudayalaya Ltd.
 NH Health City, No. 25/A, Bommasandra Industrial Area, Hosur Road, Bangalore 560 099
 Tel: +91 80 7122 2222, Extn : 2689, Direct : 080-27836966
 Fax: 080-27835208 Web: narayanahealth.org

Page 1 of 2

Figure 2: I

Study population: ? Inclusion Criteria
 ? All adult patients (more than 18 years of age) in shock requiring vasopressor to maintain MAP of 65mmHg, having a central venous access and arterial line.
 ? Exclusion Criteria
 ? Patient Refusal
 ? Pregnancy
 ? Advance directive with consensus against active resuscitation
 ? Disseminated Malignancy
 Sample size: 71
 Study design: Prospective observational study.
 Study intervention: No interventions
 Study duration: One Year

VI. Methodology
 ? All shock patients were resuscitated according to the standard protocol with fluid bolus of 30 ml/kg over 1 hour and guided therapy with fluid challenges targeting heart rate, base deficit, urine output and pulmonary congestion as per routine clinical practice.
 ? Lactate clearance was documented every 2nd hourly and VBG from Central line and ABG from Radial Line was analyzed at the same time and CO2 gap was checked every 2nd hourly.

? Screening 2D-echocardiography was done at the emergency department and inotropic agent was decided based on heart contractility.
 ? Patient demographic details, diagnosis, SOFA Score, was done in the first 6 hours of resuscitation (two hours apart) and the data was collected. Lactate and Co2 Gap were captured and documented after 24 hours of resuscitation.
 ? Aim of resuscitation was to target MAP of 65 mm and two stable lactate values 2 hours apart. If lactates had not improved then further fluid boluses were decided upon reviewing pulmonary congestion in ultrasound (M mode of lung will be done and if B lines are more than 4 then it is indicative of pulmonary congestion). The corresponding CO2 Gap was noted.
 ? First choice of vasopressor was nor-adrenaline as per the standard infusion dose. If patient requires vasopressor support despite fluid boluses then steroid in the form of injection Hydrocortisone 50mg IV every 6th hourly was administered.
 ? Antimicrobial administration management was decided by clinical examination and supportive investigations as per clinician's judgement.
 Data collection methods: Proforma Data collection form VII.

2

| | Variable | | | | |
|--------------------------|-----------|------|------|---------|---------|
| Age | Median | Mean | SD | Minimum | Maximum |
| | 57 | 54 | 16.2 | 18 | 81 |
| Gender | Male -24 | | | | |
| | Female-47 | | | | |
| SOFA score at enrollment | | Mean | | Minimum | Maximum |
| | | 9 | | 2 | 19 |
| Type of shock | Frequency | | | | |
| Anemic | 1 | | | | |
| Cardiogenic | 14 | | | | |
| Distributive | 50 | | | | |
| Hypovolemic | 3 | | | | |
| Hypoxemic | 2 | | | | |
| Neurogenic | 1 | | | | |
| Fluid requirement | Median | Mean | SD | Minimum | Maximum |
| In ml | 2000 | 2076 | 998 | 500 | 4500 |

Figure 4: Table 2 :

3

| Time point | Point biserial correlation (rpb) | Probability (p) value |
|------------|----------------------------------|-----------------------|
| 0 hour | 0.309 | 0.009 |
| 2 hours | 0.358 | 0.002 |
| 4 hours | 0.200 | 0.108 |
| 6 hours | 0.096 | 0.473 |
| 24 hours | 0.170 | 0.207 |

Figure 5: Table 3 :

4

| Time Point | Point Biserial Correlation (Rpb) | Probability (P) Value |
|------------|----------------------------------|-----------------------|
| 0 hour | -0.206 | 0.121 |
| 2 hours | -0.206 | 0.011 |
| 4 hours | -0.350 | 0.010 |
| 6 hours | -0.380 | 0.007 |
| 24 hours | -0.398 | 0.007 |

It was also observed that the pco2 gap at 0h,2h,4h, 6hours had a statistically significant positive correlation with lactate clearance.(Table 4)

Figure 6: Table 4 :

5

| Time point | Point biserial correlation (rpb) | Probability (p) value |
|------------|----------------------------------|-----------------------|
| 0 hour | 0.390 | 0.001 |
| 2 hours | 0.362 | 0.002 |
| 4 hours | 0.318 | 0.009 |
| 6 hours | 0.311 | 0.018 |
| 24 hours | 0.311 | 0.068 |
| IX. | | |

Figure 7: Table 5 :

Name: Dr. Sanjay Rao
Designation: Member Secretary
Contact No. 9538008940;
Email: nhaec@narayanahealth.org
PART II: Certificate of Consent

Figure 8:

Print Name of Researcher/person taking the consent _____
Signature of Researcher /person taking the consent _____
Date _____ Day/month/year
Print name of the impartial witness in capitals _____
Signature of impartial witness _____
Date _____ Day/month/year
Deferred Consent for Research Participation
Title of Project:

Figure 9:

.1 Confidentiality

The information that we collect from this research project will be kept confidential. Information about you that will be collected during the research will be put away and no-one but the researchers will be able to see it. Any information about you will have a number on it instead of your name. Only the researchers will know what your number is and we will lock that information up with a lock and key.

.2 Right to Refuse or Withdraw

You do not have to take part in this research if you do not wish to do so and refusing to participate will not affect your treatment at this hospital in any way. You may stop participating in the research at any time that you wish without losing any of your rights as a patient here. Your treatment at this hospital will not be affected in any way.

.3 Whom to contact

If you have any questions you may ask them now or later, even after the study has started. If you wish to ask questions later, you may contact any of the following:

The patient named below is being enrolled in this research study by deferred consent. The process of obtaining written informed consent will be deferred until after the patient is able to understand and has capacity to give consent. Written informed consent will be obtained to continue data collection after resuscitation from the patient or, if the patient lacked capacity, a legal representative. Patient's Name: _____ Date/time assessed for enrolment: ____/____/____(dd/mm/yyyy) at ____: ____ (time) Reason(s) deferred consent process is used (check all that apply): _____

The patient is unconscious or lacks capacity to understand the risks, methods and purposes of the research study.

.4 _____

No next of kin/substitute decision maker is available to provide consent, or attempts to contact them have been unsuccessful despite diligent and documented efforts. _____ A substitute decision maker _____ (name and relationship) has been contacted by telephone, and the purpose, methods and risks of participation in this study have been explained to the third party. While the substitute decision maker has given verbal consent for participation, written consent must be still be obtained.

.5 _____

No relevant prior directive by the patient is known to exist. _____ Other: _____
nature of investigator Date and Time

[Acheampong and Vincent ()] 'A positive fluid balance is an independent prognostic factor in patients with sepsis'. A Acheampong , J L Vincent . *Crit Care* 2015. 19 p. .

[Arnold et al. ()] R C Arnold , N I Shapiro , A E Jones , C Schorr , J Pope , E Casner , J E Parrillo , R P Dellinger , Trzeciak S Multi . *Center Study of Early Lactate Clearance as a Determinant of Survival in Patients with Presumed Sepsis. Shock*, 2008.

[Ducey et al. (1992)] *Arterial-venous carbon dioxide tension difference during severe hemorrhage and resuscitation. Critical care medicine*, J P Ducey , J M Lamiell , G E Gueller . 1992 Apr 1. 20 p. .

[Cuschieri et al. ()] 'Central venous-arterial carbon dioxide difference as an indicator of cardiac index'. J Cuschieri , E P Rivers , M W Donnino , M Katilius , G Jacobsen , H B Nguyen , N Pamukov , H M Horst . *Intensive Care Med* 2005. 31 p. .

[Van Beest et al. ()] 'Central venous-arterial pCO₂ difference as a tool in resuscitation of septic patients'. P A Van Beest , M C Lont , N D Holman , B Loef , M A Kuiper , E C Boerma . *Intensive Care Med* 2013. 39 p. .

[Vallée et al. ()] *Central venous-toarterial carbon dioxide difference: an additional target for goal-directed therapy in septic shock? Intensive care medicine*, F Vallée , B Vallet , O Mathe . 2008. 34 p. .

[Sun et al. ()] 'Comparison of exercise cardiac output by the fick principle using oxygen and carbon dioxide'. X.-G Sun , J E Hansen , H Ting . 10.1378/chest.118.3.631. *Chest* 2000. 118 (3) p. .

[Vincent ()] 'De Backer D Circulatory shock'. J L Vincent . *N Engl J Med* 2013. 369 p. .

[Weil et al. (1986)] 'Difference in acid-base state between venous and arterial blood during cardiopulmonary resuscitation'. M H Weil , E C Rackow , R Trevino , W Grundler , J L Falk , M I Griffel . *New England Journal of Medicine* 1986 Jul 17. 315 (3) p. .

[Jansen et al. ()] 'Early lactate-guided therapy in intensive care unit patients: a multicenter, open-label, randomized controlled trial'. T C Jansen , J Van Bommel , F J Schoonderbeek , Sleswijk Visser , S J

- 276 Van Der Klooster , J M Lima , A P Willemsen , S P Bakker , J . *Am J Respir Crit Care Med* 2010. 182 (6)
277 p. .
- 278 [Weil and Afifi ()] *Experimental and Clinical Studies on Lactate and Pyruvate as Indicators of the Severity of*
279 *Acute Circulatory Failure (Shock) Circulation*, M Weil , A A Afifi . 1970. 41 p. .
- 280 [Boyd et al. ()] 'Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure
281 are associated with increased mortality'. J H Boyd , J Forbes , T Nakada . *Crit Care Med* 2011. 39 p. .
- 282 [West (ed.) ()] *Gas transport to the periphery: how gases are moved to the peripheral tissues?*, J B West . West
283 J. B., (ed.) 1990. Seattle, WA, USA: Amazon. p. . (editor. Respiratory Physiology: The Essentials. 4th)
- 284 [Sakr et al. ()] 'Higher fluid balance increases the risk of death from sepsis: results from a large international
285 audit'. Y Sakr , Pnr Birri , K Kotfis . *Crit Care Medicine* 2017. 45 p. .
- 286 [Jones et al. ()] 'Lactate clearance versus central venous oxygen saturation as goals of early sepsis therapy'. A E
287 Jones , N Shapiro , S Trzeciak . *JAMA* 2010. 303 (8) p. .
- 288 [Kraut and Madias ()] 'Lactic acidosis'. J A Kraut , N E Madias . *N Engl JMed* 2014. 371 (24) p. .
- 289 [Ince and Sinaasappel ()] 'Microcirculatory oxygenation and shunting in sepsis and shock'. C Ince , M Sinaasappel
290 . *Crit Care Med* 1999. 27 p. .
- 291 [Varpula et al. ()] 'Mixed venous oxygen saturation cannot be estimated by central venous oxygen saturation in
292 septic shock'. M Varpula , S Karlsson , E Ruokonen , V Pettilä . *Intensive Care Med* 2006. 32 p. .
- 293 [Hernandez et al. ()] 'Persistent sepsis-induced hypotension without hyperlactatemia: Is it really septic shock'.
294 G Hernandez , R Castro , C Romero . *Journal of Critical Care* 2011. 26 p. . (e414)
- 295 [Ospina-Tascón et al. ()] 'Persistently high venous-to-arterial carbon dioxide differences during early resuscita-
296 tion are associated with poor outcomes in septic shock'. G A Ospina-Tascón , D F Bautista-Rincón , M
297 Umaña . *Crit Care* 2013. 17 p. R294.
- 298 [Mallat et al. ()] 'Ratios of central venous-to-arterial carbon dioxide content or tension to arteriovenous oxygen
299 content are better markers of global anaerobic metabolism than lactate in septic shock patients'. J Mallat ,
300 M Lemyze , M Meddour . 10.1186/s13613-016-0110-3. *Annals of Intensive Care* 2016. 6 (1) p. .
- 301 [Vallet et al. ()] 'Resuscitation of patients with septic shock: please "mind the gap'. B Vallet , M R Pinsky , M
302 Cecconi . *Intensive Care Med* 2013. 39 p. .
- 303 [Madabhushi et al. (2021)] 'Temporal Evolution of the PcvCO₂-PaCO₂/CaO₂-CcvO₂ Ratio vs Serum Lactate
304 during Resuscitation in Septic Shock'. S Madabhushi , A Trikha , R K Anand , R Ramachandran , P M Singh
305 , V Rewari . 10.5005/jp-journals-10071-24044. 35027796. PMC8693105. *Indian J Crit Care Med* 2021 Dec. 25
306 (12) p. .
- 307 [Van Beest et al. ()] 'The incidence of low venous oxygen saturation on admission to the intensive care unit: a
308 multi-center observational study in The Netherlands'. P Van Beest , J Hofstra , M Schultz , E Boerma , P
309 Spronk , M Kuiper . *Crit Care* 2008. 12 p. R33.
- 310 [Vallet et al. ()] 'Venoarterial CO₂ difference during regional ischemic or hypoxic hypoxia'. B Vallet , J L Teboul
311 , S Cain , S Curtis . *J Appl Physiol* 2000. 89 p. .